Mazdutide is a dual agonist peptide that activates both the GLP-1 receptor and glucagon receptor, offering multiple metabolic and physiological benefits:
Significant weight loss: In clinical trials, participants lost 11–14% of body weight over 48 weeks, with higher doses showing even greater results. 
Improved blood sugar control: Mazdutide reduces HbA1c levels and enhances insulin sensitivity, outperforming semaglutide in head-to-head trials for both glucose control and weight loss in patients with type 2 diabetes. 
Reduced liver fat: In studies, mazdutide reduced liver fat by up to 80.2% in patients with metabolic dysfunction-associated fatty liver disease (MAFLD), with 70% achieving normal liver fat levels after 48 weeks. 
Cardiometabolic improvements: It lowers blood pressure, improves cholesterol and triglyceride levels, reduces waist circumference, and decreases serum uric acid and liver enzymes. 
Enhanced energy expenditure: Glucagon receptor activation increases fat burning and energy use, supporting sustained weight loss. 
Neuroprotective effects: Emerging research suggests mazdutide may mitigate cognitive dysfunction associated with obesity and type 2 diabetes. 
Bone health and kidney function: It may reduce bone breakdown and increase sodium excretion, contributing to improved bone and cardiovascular health.
Mazdutide is approved in China under the brand name Xinermei for weight management and type 2 diabetes, with ongoing global trials evaluating its use in conditions like obstructive sleep apnea, heart failure, and alcohol use disorder.